Tag Archives: Cellares

Cellares and BMS Extend Collaboration to Include a Second CAR-T Asset; Kristin Yarema Appointed as Poseida’s CEO Replacing Mark Gergen

On October 10, Cellares announced an extension of its agreement with BMS to include a second CAR-T Program in Cellares’s Technology Adoption Partnership (TAP) Program (press release). A day earlier, Poseida reported a leadership transition with Kristin Yarema appointed as the new CEO expected to be effective January 1, 2024, while Mark Genger, current CEO, will transition to Executive Chairman of the company (press release). Below, Celltelligence provides insights about the expanded Cellares-BMS collaboration and speculates about which of BMS’s preclinical assets could have been partnered.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Immatics to Combine its PRAME TCR-Ts with Moderna’s Investigational mRNA Vaccine; Cellares and Lyell Enter into a New Collaboration; Adaptimmune Appoints Karen Chagin as Senior VP of Early Stage Development

On Monday, September 11, a series of cell therapy-related news items were observed:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Thoughts on BMS Joining Cellares’s Technology Adoption Partnership Program to Evaluate the Automated Production of One of Its Key CAR-Ts; Could Cellares’s Cell Shutter Become a Competitive Advantage for BMS?

On Monday, August 28, Cellares announced (press release) that BMS joined its Technology Adoption Partnership (TAP) program, entering into a proof-of-concept transfer process for the manufacturing of one of its CAR-Ts using Cellares’s proprietary Cell Shuttle platform. Below, Celltelligence provides insights into the features of Cellares’s end-to-end automated process for cell therapy production while discussing the potential competitive advantage that this partnership could represent for BMS.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Why Poseida+Cellares Matters to Novartis; Poseida’s P-BCMA-ALLO1 Allogeneic Ph1 Trial in R/R MM

On Wednesday, July 14, Cellares announced (press release) that Poseida Therapeutics has joined their Early Access Partnership Program (EAPP). Of note, the EAPP was created in 2020 to provide participants visibility and early access to Cellares’s Cell Shuttle manufacturing platform. On the same day, a new Poseida P-BCMA-ALLO1 (allogeneic BCMA CAR-T) Ph1 trial for r/r MM was observed on CT.gov. Below, Celltelligence provides insights on how Poseida’s early access to the Cell Shuttle may increase the likelihood that Novartis could acquire Poseida as well as thoughts on Poseida’s new P-BCMA-ALLO1 Ph1 study.  

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.